Retrospective 148 hospitalized COVID-19 patients showing significantly lower mortality (67% reduction) with moderately high-dose vitamin D3 treatment (30,000 IU for 3 days or 12,000 IU for 7 days followed by 3,000 IU daily), regardless of baseline vitamin D levels. Subgroup analysis of 30 patients showed that treatment resolved deficiencies within 4 days without exceeding normal ranges. The study compared two departments at Semmelweis University, where one department administered vitamin D3 and the other did not. The treatment group had a higher incidence of chronic kidney disease (statistically significant) and was slightly older and had higher severity at baseline (without statistical significance).
30 studies are RCTs, which show efficacy with
p=0.0000032.
|
risk of death, 67.3% lower, RR 0.33, p < 0.001, treatment 10 of 76 (13.2%), control 29 of 72 (40.3%), NNT 3.7.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Sümegi et al., 30 Jan 2025, retrospective, Hungary, peer-reviewed, mean age 67.5, 8 authors, study period December 2022 - April 2023, dosage 30,000IU days 1-3, 3,000IU days 4-28, 30,000IU for 3 days or 12,000IU for 7 days, followed by 3,000IU daily.
Contact: takacs.istvan@semmelweis.hu.
